Literature DB >> 28858287

Optimized retroviral transduction of mouse T cells for in vivo assessment of gene function.

Makoto Kurachi1,2, Junko Kurachi1,2, Zeyu Chen1,2, John Johnson2,3, Omar Khan1,2, Bertram Bengsch1,2, Erietta Stelekati1,2, John Attanasio1,2, Laura M McLane1,2, Michio Tomura4, Satoshi Ueha5, E John Wherry1,2.   

Abstract

Retroviral (RV) expression of genes of interest (GOIs) is an invaluable tool and has formed the foundation of cellular engineering for adoptive cell therapy in cancer and other diseases. However, monitoring of transduced T cells long term (weeks to months) in vivo remains challenging because of the low frequency and often poor durability of transduced T cells over time when transferred without enrichment. Traditional methods often require additional overnight in vitro culture after transduction. Moreover, in vitro-generated effector CD8+ T cells enriched by sorting often have reduced viability, making it difficult to monitor the fate of transferred cells in vivo. Here, we describe an optimized mouse CD8+ T-cell RV transduction protocol that uses simple and rapid Percoll density centrifugation to enrich RV-susceptible activated CD8+ T cells. Percoll density centrifugation is simple, can be done on the day of transduction, requires minimal time, has low reagent costs and improves cell recovery (up to 60%), as well as the frequency of RV-transduced cells (∼sixfold over several weeks in vivo as compared with traditional methods). We have used this protocol to assess the long-term stability of CD8+ T cells after RV transduction by comparing the durability of T cells transduced with retroviruses expressing each of six commonly used RV reporter genes. Thus, we provide an optimized enrichment and transduction approach that allows long-term in vivo assessment of RV-transduced T cells. The overall procedure from T-cell isolation to RV transduction takes 2 d, and enrichment of activated T cells can be done in 1 h.

Entities:  

Mesh:

Year:  2017        PMID: 28858287      PMCID: PMC6020692          DOI: 10.1038/nprot.2017.083

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  33 in total

1.  Notch1 regulates maturation of CD4+ and CD8+ thymocytes by modulating TCR signal strength.

Authors:  D J Izon; J A Punt; L Xu; F G Karnell; D Allman; P S Myung; N J Boerth; J C Pui; G A Koretzky; W S Pear
Journal:  Immunity       Date:  2001-03       Impact factor: 31.745

2.  Efficient transduction of murine primary T cells requires a combination of high viral titer, preferred tropism, and proper timing of transduction.

Authors:  Tong Zhang; Tom C Tsang; David T Harris
Journal:  J Hematother Stem Cell Res       Date:  2003-02

3.  Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.

Authors:  Sid P Kerkar; Luis Sanchez-Perez; Shicheng Yang; Zachary A Borman; Pawel Muranski; Yun Ji; Dhanalakshmi Chinnasamy; Andrew D M Kaiser; Christian S Hinrichs; Christopher A Klebanoff; Christopher D Scott; Luca Gattinoni; Richard A Morgan; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2011-05       Impact factor: 4.456

4.  Overview of the retrovirus transduction system.

Authors:  C Cepko; W Pear
Journal:  Curr Protoc Mol Biol       Date:  2001-05

5.  Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen.

Authors:  H Pircher; K Bürki; R Lang; H Hengartner; R M Zinkernagel
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

6.  Rapid separation of Arabidopsis male gametophyte developmental stages using a Percoll gradient.

Authors:  Nikoleta Dupl'áková; Petre I Dobrev; David Reňák; David Honys
Journal:  Nat Protoc       Date:  2016-09-01       Impact factor: 13.491

7.  Activation conditions determine susceptibility of murine primary T-lymphocytes to retroviral infection.

Authors:  A B Hagani; I Rivière; C Tan; A Krause; M Sadelain
Journal:  J Gene Med       Date:  1999 Sep-Oct       Impact factor: 4.565

8.  Retroviral transduction of murine hematopoietic stem cells.

Authors:  Peter Haviernik; Yi Zhang; Kevin D Bunting
Journal:  Methods Mol Biol       Date:  2008

9.  Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.

Authors:  Cor H J Lamers; Ralph A Willemsen; Barbara A Luider; Reno Debets; Reinder L H Bolhuis
Journal:  Cancer Gene Ther       Date:  2002-07       Impact factor: 5.987

Review 10.  Transcriptional control of effector and memory CD8+ T cell differentiation.

Authors:  Susan M Kaech; Weiguo Cui
Journal:  Nat Rev Immunol       Date:  2012-10-19       Impact factor: 53.106

View more
  18 in total

1.  TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision.

Authors:  Zeyu Chen; Zhicheng Ji; Shin Foong Ngiow; Sasikanth Manne; Zhangying Cai; Alexander C Huang; John Johnson; Ryan P Staupe; Bertram Bengsch; Caiyue Xu; Sixiang Yu; Makoto Kurachi; Ramin S Herati; Laura A Vella; Amy E Baxter; Jennifer E Wu; Omar Khan; Jean-Christophe Beltra; Josephine R Giles; Erietta Stelekati; Laura M McLane; Chi Wai Lau; Xiaolu Yang; Shelley L Berger; Golnaz Vahedi; Hongkai Ji; E John Wherry
Journal:  Immunity       Date:  2019-10-09       Impact factor: 31.745

2.  Intrinsic IL-2 production by effector CD8 T cells affects IL-2 signaling and promotes fate decisions, stemness, and protection.

Authors:  Shannon M Kahan; Rakesh K Bakshi; Jennifer T Ingram; R Curtis Hendrickson; Elliot J Lefkowitz; David K Crossman; Laurie E Harrington; Casey T Weaver; Allan J Zajac
Journal:  Sci Immunol       Date:  2022-02-11

3.  High-Efficiency Retroviral Transduction for Type 1 Regulatory T Cell Differentiation.

Authors:  Michael C McGee; Avery August; Weishan Huang
Journal:  Bio Protoc       Date:  2022-09-05

4.  Translational regulation of TFH cell differentiation and autoimmune pathogenesis.

Authors:  Preeyam S Patel; Sandra Pérez-Baos; Beth Walters; Margo Orlen; Angelina Volkova; Kelly Ruggles; Christopher Y Park; Robert J Schneider
Journal:  Sci Adv       Date:  2022-06-24       Impact factor: 14.957

5.  Naïve Primary Mouse CD8+ T Cells Retain In Vivo Immune Responsiveness After Electroporation-Based CRISPR/Cas9 Genetic Engineering.

Authors:  Petra Pfenninger; Laura Yerly; Jun Abe
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

6.  Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics.

Authors:  Josephine R Giles; Shin Foong Ngiow; Sasikanth Manne; Amy E Baxter; Omar Khan; Ping Wang; Ryan Staupe; Mohamed S Abdel-Hakeem; Hua Huang; Divij Mathew; Mark M Painter; Jennifer E Wu; Yinghui Jane Huang; Rishi R Goel; Patrick K Yan; Giorgos C Karakousis; Xiaowei Xu; Tara C Mitchell; Alexander C Huang; E John Wherry
Journal:  Nat Immunol       Date:  2022-10-21       Impact factor: 31.250

7.  In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer.

Authors:  Zeyu Chen; Eri Arai; Omar Khan; Zhen Zhang; Shin Foong Ngiow; Yuan He; Hua Huang; Sasikanth Manne; Zhendong Cao; Amy E Baxter; Zhangying Cai; Elizabeth Freilich; Mohammed A Ali; Josephine R Giles; Jennifer E Wu; Allison R Greenplate; Mohamed A Hakeem; Qingzhou Chen; Makoto Kurachi; Kito Nzingha; Viktoriya Ekshyyan; Divij Mathew; Zhuoyu Wen; Nancy A Speck; Alexis Battle; Shelley L Berger; E John Wherry; Junwei Shi
Journal:  Cell       Date:  2021-02-25       Impact factor: 41.582

8.  Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells.

Authors:  Jacob E Gillis; Tara Muijlwijk; Thao H Nguyen; Jefte M Drijvers; Emily F Gaudiano; Isaac S Harris; Martin W LaFleur; Alison E Ringel; Cong-Hui Yao; Kiran Kurmi; Vikram R Juneja; Justin D Trombley; Marcia C Haigis; Arlene H Sharpe
Journal:  Cancer Immunol Res       Date:  2020-12-04       Impact factor: 12.020

Review 9.  The role of small molecules in cell and gene therapy.

Authors:  Lewis L Brayshaw; Carlos Martinez-Fleites; Takis Athanasopoulos; Thomas Southgate; Laurent Jespers; Christopher Herring
Journal:  RSC Med Chem       Date:  2020-12-24

10.  CD147 regulates antitumor CD8+ T-cell responses to facilitate tumor-immune escape.

Authors:  Yatong Chen; Jing Xu; Xiaodong Wu; Hui Yao; Zhou Yan; Ting Guo; Wenjing Wang; Peixiao Wang; Yu Li; Xiangmin Yang; Hao Li; Huijie Bian; Zhi-Nan Chen
Journal:  Cell Mol Immunol       Date:  2020-11-11       Impact factor: 22.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.